Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma - a Randomized Controlled Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2016
At a glance
- Drugs Sorafenib (Primary) ; Vitamin K
- Indications Liver cancer
- Focus Therapeutic Use
- 17 Apr 2016 Primary endpoint has been met; (Overall Survival), according to the results published.
- 17 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.
- 17 Apr 2016 Efficacy and safety results (n=60) presented at The International Liver Congress™ 2016.